Kalms Group recently hosted a webinar together with Intralink Group as part of the Kalms Academy, focusing on opportunities in South Korea and Japan for Healthtech and Life Sciences companies.
The session, featuring insights from Charles B.C. Cielo (Japan) and Sooran Lee (Korea), explored how international companies can approach these two important healthcare markets in a more strategic, realistic, and locally adapted way. The discussion covered market trends, regulatory and reimbursement considerations, validation requirements, partnership models, and the practical steps needed to build a successful market entry strategy.
For companies looking at healthcare expansion in Asia, one message stood out clearly: South Korea and Japan offer significant opportunities, but market access must be done planful and each market requires a different approach.
Why South Korea is becoming a key market for Healthtech and Life Sciences expansion
South Korea continues to strengthen its position as a strategic bio-health market for international companies. During the webinar, Sooran Lee highlighted that the country combines strong government support, a globally aligned regulatory environment, growing innovation capacity, and attractive partnership opportunities.
South Korea offers a particularly strong setting for companies active in pharmaceuticals, medical devices, digital health, and in vitro diagnostics. The market benefits from increasing public investment in the bio-health sector, accelerated approval pathways for innovative products, and rapid adoption of AI-driven healthcare technologies. It is also increasingly seen as a gateway to broader Asian market expansion.
Another important advantage is South Korea’s strong clinical environment. The webinar underlined the country’s relevance for clinical trials, biologics, biosimilars, and AI-enabled medical technologies. This makes South Korea especially attractive for companies seeking not only market access, but also strategic collaboration, licensing, and product validation.
Key South Korea healthcare market trends discussed in the webinar
One of the central webinar themes was the pace of innovation across South Korea’s healthcare sectors.
In pharmaceuticals, major trends include AI-driven drug discovery, obesity treatments, and new modalities such as antibody-drug conjugates, targeted protein degradation, cell and gene therapy, and RNA therapeutics.
In medical devices, the discussion pointed to growing AI integration, South Korea’s global strength in dental technologies and X-ray systems, as well as increasing interest in wearable technologies.
In in vitro diagnostics, the focus is moving further toward prevention, automation, precision medicine, multiplex systems, companion diagnostics, and smart connected diagnostic platforms.
These trends show that South Korea is not only a growth market, but also a market where innovation is actively commercialised and supported by policy, infrastructure, and industrial collaboration.
South Korea market access requires early planning for regulatory approval and reimbursement
A major takeaway from the webinar was that successful market access in South Korea requires early alignment between clinical, regulatory, reimbursement, and commercial planning.
The session covered three critical areas:
- clinical trials and potential bridging studies
- regulatory approval requirements and local partner responsibilities
- reimbursement strategy, market positioning, and pricing analysis
Companies entering South Korea need to assess whether local clinical evidence is needed, understand approval expectations, define local responsibilities clearly, and prepare launch timelines accordingly. Reimbursement planning also needs to begin early, especially for companies bringing differentiated or innovative products to market.
The webinar also highlighted that Korean stakeholders often evaluate potential international partners based on their track record, flexibility, accreditation and inspection readiness, technical specifications, timelines, and price. This makes partner credibility and operational preparedness an important part of market entry success.
South Korea bio-clusters and global collaboration are driving growth
Another strong point from the webinar was the role of South Korea’s bio-clusters and innovation hubs. Regions such as Seoul, Incheon, Gyeonggi, and Daejeon play an important role in connecting research, clinical capability, government support, and industrial growth.
The webinar shared multiple examples of international collaboration across medtech, diagnostics, pharmaceuticals, and biotechnology. These included co-development projects, licensing deals, acquisitions, and open innovation partnerships. This reinforces South Korea’s position as an active global partner market for healthcare innovation, rather than simply a domestic sales destination.
Japan market access offers long-term value for the right companies
The Japan section of the webinar, led by Charles B.C. Cielo, focused on the strategic value of Japan for companies that are prepared for a longer-term and more localised market entry process.
Japan remains one of the most credible healthcare markets globally. It offers high clinical standards, strong validation potential, and a valuable environment for solutions that address unmet needs, particularly in ageing-related healthcare.
For Healthtech and Life Sciences companies, Japan can be highly relevant when the solution requires strong validation, long-term market credibility, and a strategic base for wider international deployment. The webinar made clear, however, that Japan is not a rapid-entry market. It is typically more suitable for companies with a clear long-term strategy and the willingness to invest in localisation, evidence generation, and relationship-building.
Why local partners and clinical evidence matter in Japan
One of the strongest messages from the Japan discussion was that local partners are essential.
Only a local entity or partner can submit for registration. KOL champions are often needed to support local studies, generate clinical data, and build credibility. Relationship-building is critical, and local adoption often depends on trust and influence at hospital level.
The webinar also stressed that evidence is central to adoption in Japan. Companies need to demonstrate more than regulatory compliance. They need to show clinical outcomes, quality of life benefits, operational improvements, and where relevant, cost reduction or broader health-economic value.
Importantly, this evidence must convince multiple stakeholders, including regulators, reimbursement bodies, clinicians, and professional societies. This makes evidence generation a strategic commercial issue, not just a regulatory one.
Understanding Japan’s healthcare decision-making structure
Another key point discussed by Charles B.C. Cielo was the distributed nature of healthcare decision-making in Japan.
Unlike more centralised systems, decisions in Japan are influenced by several levels, including hospitals, municipalities, and national policymakers. That means companies need to understand not only national requirements, but also how local adoption decisions are made in practice.
This has direct implications for market access strategy. Companies need to identify where decisions are made, who influences product uptake, and how local validation and pilot activity can support broader expansion.
How market entry in Japan typically happens
The webinar outlined a typical step-by-step market entry path in Japan:
- KOL champion engagement
- Small-scale pilot in Japan: typically 3 to 6 months
- Local validation: typically 6 to 12 months
- Partner identification: typically 6 to 12 months
- Submission and approval/registration
- Reimbursement: typically 12 to 24 months
- Gradual expansion: typically 12 to 24 months
This staged approach reflects the realities of the Japanese healthcare market. Market entry is usually built through validation, trust, and local proof points before broader rollout becomes feasible.
The webinar also explained when Japan may not be the right fit. Companies focused mainly on short-term revenue, those with limited localisation resources, or those whose business model does not align clearly with the Japanese healthcare system may face significant challenges.
Key market access takeaways from the Kalms Group and Intralink webinar
Across both South Korea and Japan, the webinar showed that healthcare market expansion in Asia requires more than product quality alone. Companies need to combine:
- local market understanding
- regulatory preparation
- reimbursement awareness
- evidence generation
- strong partner strategy
- realistic commercial planning
South Korea offers strong growth momentum, government-backed innovation, expanding collaboration opportunities, and an increasingly attractive environment for market access and partnership development.
Japan offers long-term strategic value, strong validation credibility, and important access to a highly respected healthcare market, but success depends on patience, local fit, and a deliberate stepwise strategy.
Kalms Group supports strategic healthcare market access planning
At the Kalms Group, we work with experienced international partners to help healthcare and medical technology companies navigate complex market access environments more effectively. The webinar with Intralink Group showed once again how important local insight and practical execution are when planning expansion into Asia.
We would like to thank everyone who joined the session and contributed to the discussion, as well as Charles B.C. Cielo (Japan) and Sooran Lee (Korea) for sharing their expertise and practical market perspectives.
If your company is exploring market access, reimbursement, regulatory strategy, or international expansion in South Korea, Japan, or any other global healthcare markets, Kalms Group together with Intralink Group would be pleased to support your next steps.
Published on: May 18, 2026
